PDCD1 and hepatocellular carcinoma: But the subsequent Checkmate-459 did not meet the primary endpoint, implying that PD-1 inhibitors are effective in hepatocellular carcinoma, but the single-agent efficacy of PD-1 inhibitors still does not fulfill therapeutic needs (69).